GlassScriptPhysician profile
Shari Hicks-Graham
NPI 1467531236
$68,106.69
in general payments reported to CMS, 2019-2025
46 companies · $3,282 in 2025
The $3,282 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,618 · 2020: $332 · 2021: $9,866 · 2022: $20K · 2023: $21K · 2024: $11K · 2025: $3,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $9,065 · Consulting Fee: $6,500 · Travel and Lodging: $353 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,250.00 |
| Food and Beverage | $9,064.58 |
| Consulting Fee | $6,500.00 |
| Travel and Lodging | $352.98 |
| Education | $105.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55,359.73 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Abbvie INC. | $2,639.97 | 2019-2025 | |
| Janssen Biotech, INC. | $1,007.85 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $807.82 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $752.15 | 2019-2025 | |
| Pfizer INC. | $746.14 | 2019-2025 | |
| Galderma Laboratories, L.P. | $690.94 | 2019-2025 | Nemluvio |
| Incyte Corporation | $661.48 | 2022-2025 | Opzelura |
| Ucb, INC. | $556.61 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $533.79 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $404.89 | 2019-2025 | Siliq, Cabtreo, Targretin |
| Amgen INC. | $380.66 | 2022-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $370.90 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $338.64 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $333.99 | 2019-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Hicks-Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.